TY - JOUR
T1 - Comprehensive characterization of perioperative reoperation following radical cystectomy
AU - Lyon, Timothy D.
AU - Boorjian, Stephen A.
AU - Shah, Paras H.
AU - Tarrell, Robert
AU - Cheville, John C.
AU - Frank, Igor
AU - Karnes, R. Jeffrey
AU - Thompson, R. Houston
AU - Tollefson, Matthew K.
N1 - Publisher Copyright:
© 2018
PY - 2019/4
Y1 - 2019/4
N2 - Introduction: To examine the nature, timing, and risk factors underlying return to the operating room (ROR) following radical cystectomy (RC). ROR has been proposed as a surgical quality metric based on data from the general surgery literature, but ROR has not been comprehensively characterized following RC. Patients and methods: We queried our institutional Cystectomy Registry from 2000 to 2016 to identify patients with ROR within 90 days of RC. Multivariable logistic regression was used to examine associations between patient features and ROR. Survival outcomes were studied based on whether ROR was necessary. Results: Of 1968 patients treated with RC, 112 (5.7%) underwent 125 reoperations within 90 days of RC, of which 93% were unanticipated and due to postsurgical complications. The most common reasons for ROR were facial dehiscence (29%), bowel obstruction (21%), and enteric anastomotic leak (8%). On multivariable analysis, increasing body mass index (odds ratio 1.04, 95% confidence interval (CI) 1.01–1.08, P = 0.045) and albumin <3.5 g/dl (odds ratio 2.15, 95% CI 1.28–3.59, P = 0.004) were associated with greater odds of ROR. Patients with a ROR had significantly decreased 5-year overall survival compared to patients who did not undergo ROR (43% vs. 55%; P = 0.003), and ROR was associated with increased all-cause mortality after multivariable adjustment (hazard ratio 1.33, 95% CI 1.01–1.74, P = 0.04). Conclusion: ROR principally occurred due to unanticipated complications and was associated with increased mortality after RC. These data suggest ROR may be a useful metric by which urological programs can track the efficacy of interventions aimed at improving perioperative care for RC patients.
AB - Introduction: To examine the nature, timing, and risk factors underlying return to the operating room (ROR) following radical cystectomy (RC). ROR has been proposed as a surgical quality metric based on data from the general surgery literature, but ROR has not been comprehensively characterized following RC. Patients and methods: We queried our institutional Cystectomy Registry from 2000 to 2016 to identify patients with ROR within 90 days of RC. Multivariable logistic regression was used to examine associations between patient features and ROR. Survival outcomes were studied based on whether ROR was necessary. Results: Of 1968 patients treated with RC, 112 (5.7%) underwent 125 reoperations within 90 days of RC, of which 93% were unanticipated and due to postsurgical complications. The most common reasons for ROR were facial dehiscence (29%), bowel obstruction (21%), and enteric anastomotic leak (8%). On multivariable analysis, increasing body mass index (odds ratio 1.04, 95% confidence interval (CI) 1.01–1.08, P = 0.045) and albumin <3.5 g/dl (odds ratio 2.15, 95% CI 1.28–3.59, P = 0.004) were associated with greater odds of ROR. Patients with a ROR had significantly decreased 5-year overall survival compared to patients who did not undergo ROR (43% vs. 55%; P = 0.003), and ROR was associated with increased all-cause mortality after multivariable adjustment (hazard ratio 1.33, 95% CI 1.01–1.74, P = 0.04). Conclusion: ROR principally occurred due to unanticipated complications and was associated with increased mortality after RC. These data suggest ROR may be a useful metric by which urological programs can track the efficacy of interventions aimed at improving perioperative care for RC patients.
KW - Bladder cancer
KW - Postoperative complications
KW - Radical cystectomy
KW - Reoperation
UR - http://www.scopus.com/inward/record.url?scp=85060213159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060213159&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2018.11.023
DO - 10.1016/j.urolonc.2018.11.023
M3 - Article
C2 - 30679081
AN - SCOPUS:85060213159
SN - 1078-1439
VL - 37
SP - 292.e11-292.e17
JO - Urologic Oncology
JF - Urologic Oncology
IS - 4
ER -